期刊文献+

程序性死亡配体-1在鼻咽癌组织中的表达及临床意义 被引量:1

Expression of Programmed Cell Death Ligand-1 in Nasopharyngeal Carcinoma and Its Clinical Significance
原文传递
导出
摘要 目的:探讨程序性死亡配体-1(PD-L1)在鼻咽癌组织中的表达及临床意义。方法:选取2015年7月-2017年6月期间在我院接受治疗的鼻咽癌患者333例,收集其鼻咽癌组织作为观察组标本,另选取同期在我院接受治疗的慢性鼻咽炎患者102例的鼻咽炎组织作为对照组标本。采用免疫组化法和逆转录-聚合酶链反应(RT-PCR)检测两组患者鼻咽组织中PD-L1蛋白和PD-L1 mRNA的表达,并分析观察组患者鼻咽癌组织中PD-L1蛋白和PD-L1 mRNA的表达与临床病理参数的关系。结果:对照组患者鼻咽炎组织中PD-L1蛋白的阳性率为0.00%(0/102),观察组患者鼻咽癌组织中PD-L1蛋白的阳性率为69.37%(231/333),两组PD-L1蛋白的阳性率比较差异有统计学意义(P<0.05)。RT-PCR结果显示,对照组患者鼻咽炎组织中未见PD-L1 mRNA表达,观察组患者鼻咽癌组织中PD-L1 mRNA的相对表达水平为(0.82±0.27),差异有统计学意义(P<0.05)。观察组患者鼻咽癌组织中PD-L1蛋白和PD-L1 mRNA的表达与年龄、性别无关(P>0.05),而TNM分期为Ⅲ-Ⅳ期、有淋巴结转移、有吸烟史患者鼻咽癌组织中PD-L1蛋白阳性率和PD-L1 mRNA的表达均高于TNM分期Ⅰ-Ⅱ期、无淋巴结转移、无吸烟史患者(P<0.05)。结论:在鼻咽癌组织中PD-L1蛋白和PD-L1 mRNA呈现高表达,且其表达与TNM分期、淋巴结转移、吸烟史有关。 Objective: To investigate the expression and clinical significance of programmed cell death ligand-1(PD-L1) in nasopharyngeal carcinoma(NPC). Methods: A total of 333 patients with nasopharyngeal carcinoma,who were treated in the First People's Hospital of Yulin from July 2015 to June 2017, were collected; the nasopharyngeal carcinoma tissues were collected as observation group, 102 cases of chronic pharyngitis during the same period were taken as control group.Immunohistochemical staining and reverse transcription polymerase chain reaction(RT-PCR) were used to detect the expression of PD-L1 and PD-L1 mRNA in the nasopharynx tissues of two groups. The relationship between the expression of PD-L1 protein and PD-L1 mRNA and the clinicopathological parameters in the patients with nasopharyngeal carcinoma were analyzed. Results: The positive rate of PD-L1 protein in the nasal pharyngitis tissue of the control group was 0.00%(0/102), the positive rate of PD-L1 protein in the nasopharyngeal carcinoma tissues of the observation group was 69.37%(231/333); the positive rates of PD-L1 protein in the two groups were statistically significant(P〈0.05). The results of RT-PCR showed that there were no expressions of PD-L1 and mRNA in the control group, the relative expression of PD-L1 and mRNA in the nasopharyngeal carcinoma tissues of the observation group was(0.82+0.27), the difference was statistically significant(P〈0.05).The expressions of PD-L1 protein and PD-L1 mRNA in the nasopharyngeal carcinoma tissues of the observation group were not related to age and sex(P〈0.05). The positive rate of PD-L1 protein and the expression of PD-L1 and mRNA in nasopharyngeal carcinoma tissues in patients with TNM stage Ⅲ-Ⅳ, lymph node metastasis and history of smoking were higher than those in patients with TNM stage Ⅰ-Ⅱ,no lymph node metastasis, and no smoking history(P〈0.05). Conclusion: The expression of PD-L1 protein and PD-L1 mRNA is highly expressed in nasopharyngeal carcinoma,and its expression is related to TNM staging,lymph node metastasis and smoking history.
作者 黄庆文 何江 阙丽琳 陈伊 李文 HUANG Qing-wen1, HE Jiang2, QUE Li-lin3, CHEN Yi1, LI Wen1(1 Department of Pathology, The First People's Hospital of Yulin, Yulin, Guangxi, 537000, China; 2 Department of Otolatyngology, The First People's Hospital of Yulin, Yulin, Guangxi, 537000, China; 3 Department of Oncology, The First People's Hospital ofYulin, Yulin, Guangxi, 537000, Chin)
出处 《现代生物医学进展》 CAS 2018年第3期528-531,536,共5页 Progress in Modern Biomedicine
关键词 程序性死亡配体-1 鼻咽癌 表达 临床意义 Programmed cell death ligand -1 Nasopharyngeal carcinoma Expression Clinical significance
  • 相关文献

参考文献7

二级参考文献43

  • 1孙祥宙,丘少鹏.膀胱癌患者术后沙培林膀胱灌注预防复发的机制初探(英文)[J].中国现代医学杂志,2004,14(13):49-51. 被引量:2
  • 2周翡,罗金红,王理伟.奈达铂联合放疗治疗晚期鼻咽癌[J].中国癌症杂志,2007,17(6):490-492. 被引量:9
  • 3彭杰文,梁汉霖,张俊凯,萧剑军,张朝珍.奈达铂治疗晚期头颈癌的临床疗效观察[J].中华肿瘤防治杂志,2007,14(10):779-781. 被引量:9
  • 4Agulnik M, Epstein JB. Nasopharyngeal carcinoma: current manage- ment, future directions and dental implications [J]. Oral Oncol, 2008, 44:617-627.
  • 5Wilko FAR, Johan P, Daan Hoffmans, et al. Volumetric Intensity- Modulated Arc Therapy Vs Conventional IMRT in Head-and-Neck Cancer: A Comparative Planning and Dosimetric Study [J]. Interna- tional Journal of Radiation Oncology Biology Physics, 2009, 74(1): 252-259.
  • 6Lee NY, Le QT. New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia tar- geting[J]. Semin Oncol, 2008, 35:236-250.
  • 7Dennis ER, Bussiere MR, Niemierko A, et al. A comparison of critical structure dose and toxicity risks in patients with low grade gliomas treated with IMRT versus proton radiation therapy[J]. Technol Cancer Res Treat, 2013, 12(1): 1-9.
  • 8Vesna Jacob, Wolfgang Bayer, Sabrina T. Astner, et al. A Planning Comparison of Dynamic 1MRT for Different Collimator Leaf Thick- nesses with Helical Tomotherapy and RapidArc for Prostate and Head and Neck Tumors [J]. Strahlentherapie und Onkologie, 2010, 186(9): 501-510.
  • 9Ng WT, Lee MC, Hung WM, et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal car- cinoma[J]. Int J Radiat Oncol Biol Phys, 2011, 79:420-428.
  • 10Nancy Lee, Jonathan Harris, Adam S Garden, et al. Intensity-Modu- lated Radiation Therapy With or Without Chemotherapy for Nasopha- ryngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225[J]. Journal of Clinical Oncology, 2009, 27(22): 3684-3690.

共引文献93

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部